Discontinuation of Eculizumab in a Patient With Atypical Hemolytic Uremic Syndrome Due to a Mutation in CFH

Am J Kidney Dis. 2016 Mar;67(3):532-3. doi: 10.1053/j.ajkd.2015.11.009. Epub 2015 Dec 23.

Authors

Sandra Habbig¹, Carsten Bergmann², Lutz T Weber³

Affiliations

¹ University Children's Hospital Cologne, Cologne, Germany; University of Cologne, Cologne, Germany. Electronic address: sandra.habbig@uk-koeln.de.
² Bioscientia Center for Human Genetics, Ingelheim, Germany; University Freiburg Medical Center, Freiburg, Germany.
³ University Children's Hospital Cologne, Cologne, Germany.

PMID: 26724167
DOI: 10.1053/j.ajkd.2015.11.009

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized / administration & dosage*
Atypical Hemolytic Uremic Syndrome* / drug therapy
Atypical Hemolytic Uremic Syndrome* / genetics
Atypical Hemolytic Uremic Syndrome* / physiopathology
Complement Factor H / genetics*
Humans
Immunologic Factors / administration & dosage
Mutation
Pharmacogenetics / methods
Precision Medicine
Secondary Prevention
Withholding Treatment

Substances

Antibodies, Monoclonal, Humanized
Immunologic Factors
Complement Factor H
eculizumab